Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis
Status:
Completed
Trial end date:
2017-05-15
Target enrollment:
Participant gender:
Summary
To establish the bioequivalence between test drug, Pimecrolimus Cream, 1% with that of
reference listed drug, Elidel® (pimecrolimus) Cream 1%, in the treatment of mild to moderate
Atopic Dermatitis.
To establish superiority of each active treatment over the placebo.